Olivier Le Moal
- Propanc Biopharma (OTCQB:PPCB) said it received a notice of allowance from the European Patent Office (EPO) for claims involving compositions of proenzymes to treat cancer.
- The company added that it was its second patent application allowed in this jurisdiction and expires in November 2036.
- Propanc noted that a third patent application is currently under examination at the EPO for a method to treat cancer stem cells, which was allowed in March this year by the U.S. Patent and Trademark Office (USPTO).
- Propanc said the field of the invention covers future dosing in planned clinical studies for its lead product candidate PRP.